TLR7 and neoplasm: However, we already demonstrated the immunogenicity of the non-glycosylated MUC1 peptide in previous work, and the combination of the naked MUC1 sequence and the TLR7 agonist (T7 + MUC1) could be an effective tumor vaccine [14].